These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 17432922)

  • 1. When should levodopa therapy be initiated in patients with Parkinson's disease?
    Halkias IA; Haq I; Huang Z; Fernandez HH
    Drugs Aging; 2007; 24(4):261-73. PubMed ID: 17432922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in the pharmacological treatment of Parkinson's disease.
    Tuite P; Riss J
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa strengths and weaknesses.
    Jankovic J
    Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Strategies in Early Parkinson's Disease.
    Marsili L; Marconi R; Colosimo C
    Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
    Melamed E; Zoldan J; Galili-Mosberg R; Ziv I; Djaldetti R
    J Neural Transm Suppl; 1999; 56():173-83. PubMed ID: 10370911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Parkinson's disease: what is the best approach to treatment.
    Hristova AH; Koller WC
    Drugs Aging; 2000 Sep; 17(3):165-81. PubMed ID: 11043817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
    Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
    J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa in the treatment of Parkinson's disease: current status and new developments.
    Salat D; Tolosa E
    J Parkinsons Dis; 2013 Jan; 3(3):255-69. PubMed ID: 23948989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.